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Objective: To make a review of studies that assessed the outcomes of GnRH agonist oocyte
triggering in comparison with hCG in prevention of ovarian hyperstimulation syndrome and
pregnancy rates.
Methods: A systematic review of studies presented in the following database: PUBMED, Lilacs
and Scielo submitted from January 2005 to October 2015. The keywords were ovulation
induction, ovarian hyperstimulation syndrome and gonadotropin releasing hormone.
Results: One hundred ﬁfty-four articles were found. From these, twelve studies were com-
pletely analyzed. Eight fulﬁlled the inclusion criteria and one was included after the
bibliographic review of the previous ones. From these nine submitted articles, two  are
retrospective and the others are prospective.
Conclusion: The use of GnRH agonist for oocyte triggering was comparable with hCG and
showed low frequency of ovarian hyperstimulation syndrome.
© 2016 Sociedade Brasileira de Reproduc¸a˜o Humana. Published by Elsevier Editora Ltda.
This  is an open access article under the CC BY-NC-ND license (http://creativecommons.
org/licenses/by-nc-nd/4.0/).
Resultados  da  maturac¸ão  oocitária  ﬁnal  com  agonistas  do  GnRH  nos
ciclos  de  reproduc¸ão  assistida:  uma  revisão  sistemática
alavras-chave:
ormônio liberador
r  e  s  u  m  o
Objetivo: Fazer uma revisão dos estudos que avaliaram os desfechos do agonista de GnRH no
ovócito em comparac¸ão com hCG na prevenc¸ão da síndrome de hiperestimulac¸ão ovarianaão.e gonadotropina e  nas taxas de gestac¸Please cite this article in press as: Gomes LB, et al. Outcomes of GnRH agonist triggering in assisted reproductive technology: a systematic
review. Reprod Clim. 2016. http://dx.doi.org/10.1016/j.recli.2016.07.003
índrome de hiperestimulac¸ão
variana
axa de gestac¸ão
Métodos: Revisão sistemática de estudos presentes nos seguintes bancos de dados: Pubmed,
Lilacs e Scielo, apresentados de janeiro de 2005 até outubro de 2015. As palavras-chave
foram induc¸ão da ovulac¸ão, síndrome de hiperestimulac¸ão ovariana e hormônio liberador
de  gonadotropina.
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Resultados: Foram localizados 154 artigos; 12 foram integralmente analisados; oito
preenchiam os critérios de inclusão; um foi incluído depois da revisão bibliográﬁca dos
estudos precedentes. Dentre esses nove artigos apresentados, dois são retrospectivos e os
demais são prospectivos.
Conclusão: O uso do agonista de GnRH para a induc¸ão do ovócito foi comparável ao hCG,
demonstrou baixa frequência de síndrome de hiperestimulac¸ão ovariana.
©  2016 Sociedade Brasileira de Reproduc¸a˜o Humana. Publicado por Elsevier Editora
Ltda. Este e´ um artigo Open Access sob uma licenc¸a CC BY-NC-NDIntroduction
The gonadotropin releasing hormone (GnRH) agonist has
been used for triggering ﬁnal oocyte maturation in in vitro
fertilization (IVF) for a few years. The ﬁrst authors to
document this practice were Gonan and Casper, in 1990,
obtaining in their study with eighteen patients, oocyte quality
and quantity outcomes similar to hCG triggering.1 How-
ever, It was only with the rise of GnRH antagonist protocol
that its use was truly propagated in the beginning of this
century.2,3
The prevention of ovarian hyperstimulation syndrome
(OHSS), fearsome iatrogenic complication of human repro-
duction techniques, became the main indication of this type
of triggering. Several studies showed incidence’s reduction,
mostly because of the early induction and short duration of
LH surge.4–6
The aim of this study is to review the GnRH agonist trigg-
ering outcomes in comparison with hCG in the prevention of
ovarian hyperstimulation syndrome and in pregnancy rates.
Materials  and  methods
The keywords used for the construction of this article were:
ovulation induction, ovarian hyperstimulation syndrome and
gonadotropin releasing hormone. The following database:
Pubmed, Lilacs and Scielo were analyzed. The articles pub-
lished from January of 2005 to October of 2015 in Portuguese,
Spanish and English were selected by two researchers inde-
pendently. If disagreement a third researcher was consulted.
The inclusion and exclusion criteria were based on the main
systematic reviews about the subject available. The inclu-
sion criteria were: studies using GnRH agonist (GnRHa) for
triggering that described its outcomes in pregnancy rates
and/or OHSS, women with age between 18 and 40 years,
BMI  between 18 and 35 kg/m2, non-smokers and with ovar-
ian reserve of 3 or more  antral follicles. It was excluded from
this review, women that had any uterine pathology or malfor-
mation.
One hundred and ﬁfty four published articles were found
considering the keywords and ﬁlters used in association. After
their abstracts reading, twelve articles were selected for pos-Please cite this article in press as: Gomes LB, et al. Outcomes of GnRH a
review. Reprod Clim. 2016. http://dx.doi.org/10.1016/j.recli.2016.07.003
terior full read. From these, nine ﬁt the inclusion criteria. The
method was described in the form of a ﬂuxogram represented
in Fig. 1. As a systematic review, approval of the local Research
Ethics Committee wasn’t necessary.(http://creativecommons.org/licenses/by-nc-nd/4.0/).
Results
The articles data were summed up in Table 1 for comparative
analysis. From 9 selected studies, seven were prospective
including randomized clinical trials and cohorts. The oldest
paper is from 2005 by Kolibianakis et al. fulﬁlled in two
human reproduction centers, one in Belgium and the other
in Germany whilst the most recent is from 2014, by Decleer
et al. The highest population assayed was in Spain with 1171
women and the smallest in Cyprus with only 44 patients.
Discussion
The GnRH agonist use for triggering oocyte ﬁnal maturation
was propagated as prevention to ovarian hyperstimulation
syndrome for its effect in LH surge. It has shorter half-life
than hCG stimulation and decreases the vascular endothelial
factor growth (VEFG1) production which is the main developer
of the syndrome.7
Kolibianakis et al.,8 in his randomized clinical trial, with
106 women in two European centers found in one of them
statistic signiﬁcant decrease (p = 0.012) in pregnancy rate in the
agonist use group (5.6% vs 41.7%) and a clear reduction, though
not statistic signiﬁcant, in the same group in the second center
(2.9% vs 16.7%). Higher implantation rate was also described in
the hCG group and no OHSS case was observed in neither one.
Thus, no advantaged of the agonist was noted in the study.
However, the others screened studies demonstrated better
results. Melo et al.9 made a prospective randomized cohort
with 100 oocyte donors. No OHSS was found in the agonist
group vs 16% in hCG group whilst the implantation, preg-
nancy and miscarriage rates were similar in both groups. Bodri
et al.,10 in the same year, observed resembling results in his
retrospective study with higher population (n = 1171). Thirteen
cases of OHSS (2.08%) in the hCG group and none in the agonist
one was found and comparable outcomes between the groups
as clinical pregnancy rates: 42.4% vs 38.8% and implantation
rate: 29.1% vs 25.9%.
Simanoglu et al.,11 in a prospective study with oocyte
donors, also found absence of the syndrome in the agonist
group against 4 cases in the hCG one.
The association of ﬁnal oocyte maturation with GnRH ago-gonist triggering in assisted reproductive technology: a systematic
nist and posterior freezing of oocyte and embryos (freeze-all
strategy) is another method. Devroey12 proposed the pos-
sibility of an OHSS free-clinic with this approach in an
opinion article. Griesinger et al.13 used this strategy to evaluate
Please cite this article in press as: Gomes LB, et al. Outcomes of GnRH agonist triggering in assisted reproductive technology: a systematic
review. Reprod Clim. 2016. http://dx.doi.org/10.1016/j.recli.2016.07.003
ARTICLE IN PRESSRECLI-126; No. of Pages 5
r  e p r o d c l i m . 2 0 1 6;x x x(x x):xxx–xxx 3
References 
review
1 article included 
Kolibianakis et al. 
Database: PUBMED, 
Lilacs e Scielo  
Filters: 
Language: portuguese , 
english and spanish. 
Period: 2005 to 2015 
Keywords: 
- In duction  ovulation;   
- Ovarian hyperstimulation 
syndrome ; 
- Gonadot ropin  releasin g 
hormone 
154 articles were found 
with posterior abstract 
reading. 
12 articles  screened  to 
full-text  read ing 
Inclusion cr iteria: 
• Triggeri ng with  GnRH 
agonist; 
• Ou tcomes described in th e 
study ; 
• Ovarian  re serve  of  3 or more  
antral follicl es; 
• BMI:  18 -35Kg /m²;  
• 18  to  40  ye ars-old ; 
• Non-smokers ; 
8 article s inc lude d 
Bod ri et  al.  2009  
Melo et  al.  2009  
Simanoglu  et  al.  2009  
Griesinger et al.  2011 
Tal Imba r et  al.  2012  
Ilidromiti  et  al.  2013 
Humaidan et al.  2013 
Declee r et al.  2014 
Total de 9 include d artic les
Fig. 1 – Fluxogram of the methodology used in this systematic review.
Table 1 – Outcomes described in the systematic review.
References Year Country Design Population OHSS Implantation Rate Pregnancy rate
GnRHa hCG GnRHa hCG GnRHa hCG
Kolibianakis et al. 2005 Belgium/Germany Prospective 106 Absent Absent 6.8% 22.6% 5.6%/2.9 41.7%/16.7%
Bodri et al. 2009 Spain Retrospective 1171 Absent 13 cases 25.9% 29.1% 38.8% 42.1%
Melo et al. 2009 Spain Prospective 100 Absent 8 cases 30.4% 27.1% 52% 58%
Sismanoglu et al. 2009 Cyprus Prospective 44 Absent 4 cases 32.93% 3653% 6881% 69%
Griesinger et al.a 2011 Germany Prospective 51 4 cases Absent Unquoted Unquoted
Tal Imbar et al. 2012 Israel Prospective 110 Absent Absent 36% Unquoted 52% Unquoted
Iliodromiti et al. 2013 Vietnam Retrospective 620 1 case 18 cases 14.2% 16.6% 30% 30%
Humaidan et al.b 2013 Denmark Prospective 384 2 cases 2 cases 35.5% 29.5% 34.6% 28.6%
Decleer et al.b 2014 Belgium Prospective 120 Absent Absent 22% 34% 31.1% 44.1%
GnRHa, gonadotropin releasing hormone antagonis; hCG, human chorionic gonadotropin; OHSS, ovarian hyperstimulation síndrome.
a Study non-comparative with hCG.
b Studies show a comparison between hCG with GnRH agonist and isolated hCG.
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its results in a prospective multicenter study with OHSS
high-risk women. Of 51 patients, 4 (7.9%) developed the syn-
drome, being one of them a severe case. Fatemi et al.14 also
presented two clinical cases in United Arab Emirates and
India who developed the severe case of the pathology with
the use of the same approach, what demonstrates that an
OHSS free-clinic is chimeric. Meanwhile, the pregnancy and
live births rates were favorable with the protocol aforemen-
tioned.
Ilidromiti et al.15 compared the maturation with GnRH ago-
nist associated with luteal phase support with progesterone
in patients with higher risk of OHSS (n = 363) with patients
who  received conventional dose of hCG (n = 257) in a retro-
spective cohort. Only one case of OHSS occurred in the agonist
group against 18 cases in the control group. Clinical pregnancy
and live birth rates (30% and 29.7%, respectively) were similar
whilst miscarriage rate was lower in the agonist group. Tal
Imbar,16 in an observational prospective study, associated the
use of agonist as trigger with luteal support with progesterone
and freeze-all strategies and comparing with isolated use of
agonist.
Humaidan et al.17 produced a prospective randomized
study also comparing the use of hCG with GnRHa and luteal
support, but with use of hCG, instead of progesterone. Three
hundred and eighty four women were classiﬁed in higher and
lower risk of OHSS (criteria used was the presence of more
than 14 ovarian follicles). In the higher risk group (n = 118), half
of the patients received GnRHa with 1500 U hCG support and
the remaining received 5000 U hCG alone. In the lower risk
group the support was made with two doses of hCG. Before
this conduct, none cases of OHSS were observed in the higher
risk using GnRHa while two cases of the syndrome in the hCG
alone group occurred (1.6%) and the reverse happened in the
lower risk patients; two of the agonist group developed OHSS
vs none in the hCG group. This strongly indicates the use of
agonist only in higher risk patients. Other results as implan-
tation, pregnancy and miscarriage rates resembled between
the groups. Ilidromiti et al.,18 in the same year, through an
multicenter retrospective study showed improvement of preg-
nancy rates with this luteal support with hCG but with OHSS
occurrence (0.72%).
Decleer et al.,19 in his randomized clinical trial, compared
the oocyte ﬁnal maturation (GnRH +5000 U hCG) with the use
of hCG alone. In neither group OHSS occurred as implantation
and pregnancy rates didn’t show statistic differences what
didn’t justify the use of the combined medication.
Conclusion
The use of GnRH agonist for oocyte ﬁnal maturation was
comparable with hCG and some studies didn’t demonstrate
statistic differences in implantation and pregnancy rates.
Few studies that associate hCG with GnRHa didn’t demon-
strate statistic differences in the rates aforementioned.
The efﬁcacy in decrease ovarian hyperstimulation syndromePlease cite this article in press as: Gomes LB, et al. Outcomes of GnRH a
review. Reprod Clim. 2016. http://dx.doi.org/10.1016/j.recli.2016.07.003
also is clear when not associated with hCG. The association
with freeze-all strategy promotes even higher reduction of
the syndrome. However, its complete elimination remains a
challenge. x x(x  x):xxx–xxx
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